{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:47:59Z","timestamp":1792723679080,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Evaluation of antimalarial drug efficacy against\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    requires molecular correction to distinguish recrudescence from new infections by comparing parasite genotypes before treatment and in recurrent infections. We aimed to assess the utility of nanopore sequencing in providing rapid corrected drug efficacy estimates, particularly in patients from high-transmission settings where polyclonal infections are common. We optimized a multiplexed AmpSeq panel targeting six microhaplotypes to achieve high and uniform coverage. The assay\u2019s sensitivity and specificity for detecting minority clones in polyclonal infections and its reproducibility were evaluated using a range of mixtures of four\n                    <jats:italic>P. falciparum<\/jats:italic>\n                    laboratory strains at defined ratios. Genetic diversity across the microhaplotype markers was assessed using 20 paired patient samples from a clinical trial. A custom bioinformatics workflow was used to infer haplotypes from polyclonal infections, including minority clones, applying rigorous cutoff criteria for accurate haplotype calling. The nanopore AmpSeq assay provided uniform and high read coverage across all six microhaplotype markers in both laboratory strain mixtures and patient samples. It demonstrated high sensitivity in detecting minority clones (as low as 1:100:100:100 in the 3D7:K1:HB3:FCB1 strain mixtures), high specificity (false-positive haplotypes\u2009&lt;\u20090.01%), and robust reproducibility (intra-assay: 98%; inter-assay: 97%). The markers exhibited high genetic diversity (highest for\n                    <jats:italic>cpmp<\/jats:italic>\n                    with H\n                    <jats:sub>E<\/jats:sub>\n                    =0.99 and 28 unique haplotypes). Across the paired patient samples, the assay consistently distinguished recrudescence from new infections in 17\/20 cases (85%) for all six markers. Our study demonstrates the feasibility and robustness of nanopore AmpSeq for distinguishing recrudescence from new infections in paired samples from clinical drug trials, offering a promising tool to obtain rapid corrected estimates of drug failure.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-20925-7","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:15:09Z","timestamp":1761128109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rapid multiplexed nanopore amplicon sequencing to distinguish Plasmodium falciparum recrudescence from new infection in antimalarial drug trials"],"prefix":"10.1038","volume":"15","author":[{"given":"Aurel","family":"Holzschuh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Lerch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Nsanzabana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"20925_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"M Dondorp Arjen","year":"2009","unstructured":"Dondorp Arjen, M. et al. Artemisinin resistance in plasmodium falciparum malaria. N. Engl. J. Med. 361, 455\u2013467 (2009).","journal-title":"N. Engl. J. Med."},{"key":"20925_CR2","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana, A. et al. Association of plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet. Infect. Dis. 21, 1120\u20131128 (2021).","journal-title":"Lancet. Infect. Dis"},{"key":"20925_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"Balikagala","year":"2021","unstructured":"Balikagala et al. Evidence of Artemisinin-Resistant malaria in Africa. N. Engl. J. Med. 385, 1163\u20131171 (2021).","journal-title":"N. Engl. J. Med."},{"key":"20925_CR4","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2210956","volume":"389","author":"S Mihreteab","year":"2023","unstructured":"Mihreteab, S. et al. Increasing prevalence of Artemisinin-Resistant HRP2-Negative malaria in Eritrea. N. Engl. J. Med. 389, 1191\u20131202 (2023).","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"20925_CR5","doi-asserted-by":"publisher","first-page":"00362","DOI":"10.1016\/S1473-3099(24)00362-1","volume":"S1473-3099","author":"DS Ishengoma","year":"2024","unstructured":"Ishengoma, D. S. et al. Evidence of Artemisinin partial resistance in Northwestern tanzania: clinical and molecular markers of resistance. Lancet Infect. Dis. S1473-3099 (24), 00362\u201300361. https:\/\/doi.org\/10.1016\/S1473-3099(24)00362-1 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"20925_CR6","unstructured":"WHO. World malaria report 2023. Geneva: World Health Organization. (2023)."},{"key":"20925_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey, F. et al. A molecular marker of artemisinin-resistant plasmodium falciparum malaria. Nature 505, 50\u201355 (2014).","journal-title":"Nature"},{"key":"20925_CR8","unstructured":"WHO. Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy: Genotyping To Identify Parasite Populations : Informal Consultation Organized by the Medicines for Malaria Venture and Cosponsored by the World Health Organization, 29\u201331 May 2007, Amsterdam, the Netherlands (World Health Organization, 2008)."},{"key":"20925_CR9","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S1473-3099(19)30426-8","volume":"20","author":"I Felger","year":"2020","unstructured":"Felger, I., Snounou, G., Hastings, I., Moehrle, J. J. & Beck H.-P. PCR correction strategies for malaria drug trials: updates and clarifications. Lancet. Infect. Dis. 20, e20\u2013e25 (2020).","journal-title":"Lancet. Infect. Dis"},{"key":"20925_CR10","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.4269\/ajtmh.20-1481","volume":"104","author":"MM Plucinski","year":"2021","unstructured":"Plucinski, M. M. et al. Variation in calculating and reporting antimalarial efficacy against plasmodium falciparum in Sub-Saharan africa: A systematic review of published reports. Am. J. Trop. Med. Hyg. 104, 1820 (2021).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"20925_CR11","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1186\/s12864-017-4260-y","volume":"18","author":"A Lerch","year":"2017","unstructured":"Lerch, A. et al. Development of amplicon deep sequencing markers and data analysis pipeline for genotyping multi-clonal malaria infections. BMC Genom. 18, 864 (2017).","journal-title":"BMC Genom."},{"key":"20925_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-54203-0","volume":"9","author":"M Gruenberg","year":"2019","unstructured":"Gruenberg, M., Lerch, A., Beck, H. P. & Felger, I. Amplicon deep sequencing improves plasmodium falciparum genotyping in clinical trials of antimalarial drugs. Sci. Rep. 9, 1\u201312 (2019).","journal-title":"Sci. Rep."},{"key":"20925_CR13","doi-asserted-by":"crossref","unstructured":"Schnoz, A. et al. Genotyping methods to distinguish plasmodium falciparum recrudescence from new infection for the assessment of antimalarial drug efficacy: an observational, single-centre, comparison study. The Lancet Microbe 0, (2024).","DOI":"10.1016\/S2666-5247(24)00153-8"},{"key":"20925_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa527","author":"SK Tessema","year":"2020","unstructured":"Tessema, S. K. et al. Sensitive, highly multiplexed sequencing of microhaplotypes from the plasmodium falciparum heterozygome. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiaa527 (2020).","journal-title":"J. Infect. Dis."},{"key":"20925_CR15","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1038\/s41467-023-39417-1","volume":"14","author":"A Holzschuh","year":"2023","unstructured":"Holzschuh, A. et al. Multiplexed ddPCR-amplicon sequencing reveals isolated plasmodium falciparum populations amenable to local elimination in Zanzibar, Tanzania. Nat. Commun. 14, 3699 (2023).","journal-title":"Nat. Commun."},{"key":"20925_CR16","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1111\/1755-0998.13622","volume":"22","author":"E LaVerriere","year":"2022","unstructured":"LaVerriere, E. et al. Design and implementation of multiplexed amplicon sequencing panels to serve genomic epidemiology of infectious disease: A malaria case study. Mol. Ecol. Resour. 22, 2285\u20132303 (2022).","journal-title":"Mol. Ecol. Resour."},{"key":"20925_CR17","doi-asserted-by":"publisher","first-page":"e17292","DOI":"10.1111\/mec.17292","volume":"33","author":"A Holzschuh","year":"2024","unstructured":"Holzschuh, A. et al. Plasmodium falciparum transmission in the highlands of Ethiopia is driven by closely related and clonal parasites. Mol. Ecol. 33, e17292 (2024).","journal-title":"Mol. Ecol."},{"key":"20925_CR18","doi-asserted-by":"publisher","first-page":"10737","DOI":"10.1038\/s41598-025-94716-5","volume":"15","author":"A Aranda-D\u00edaz","year":"2025","unstructured":"Aranda-D\u00edaz, A. et al. Sensitive and modular amplicon sequencing of plasmodium falciparum diversity and resistance for research and public health. Sci. Rep. 15, 10737 (2025).","journal-title":"Sci. Rep."},{"key":"20925_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12936-019-2856-1","volume":"18","author":"AM Early","year":"2019","unstructured":"Early, A. M. et al. Detection of low-density plasmodium falciparum infections using amplicon deep sequencing. Malar. J. 18, 219 (2019).","journal-title":"Malar. J."},{"key":"20925_CR20","doi-asserted-by":"publisher","unstructured":"Jones, S. et al. Should Deep-Sequenced amplicons become the new gold standard for analyzing malaria drug clinical trials? Antimicrob. Agents Chemother. 65 https:\/\/doi.org\/10.1128\/aac.00437-21 (2021).","DOI":"10.1128\/aac.00437-21"},{"key":"20925_CR21","doi-asserted-by":"publisher","unstructured":"Gerlovina, I., Gerlovin, B., Rodr\u00edguez-Barraquer, I. & Greenhouse, B. Dcifer: an IBD-based method to calculate genetic distance between polyclonal infections. Genetics iyac126 https:\/\/doi.org\/10.1093\/genetics\/iyac126 (2022).","DOI":"10.1093\/genetics\/iyac126"},{"key":"20925_CR22","doi-asserted-by":"publisher","first-page":"8286","DOI":"10.1038\/s41598-018-26334-3","volume":"8","author":"LR Runtuwene","year":"2018","unstructured":"Runtuwene, L. R. et al. Nanopore sequencing of drug-resistance-associated genes in malaria parasites, plasmodium falciparum. Sci. Rep. 8, 8286 (2018).","journal-title":"Sci. Rep."},{"key":"20925_CR23","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41564-023-01516-6","volume":"8","author":"ST Girgis","year":"2023","unstructured":"Girgis, S. T. et al. Drug resistance and vaccine target surveillance of plasmodium falciparum using nanopore sequencing in Ghana. Nat. Microbiol. 8, 2365\u20132377 (2023).","journal-title":"Nat. Microbiol."},{"key":"20925_CR24","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/s41467-024-45688-z","volume":"15","author":"M de Cesare","year":"2024","unstructured":"de Cesare, M. et al. Flexible and cost-effective genomic surveillance of P. falciparum malaria with targeted nanopore sequencing. Nat. Commun. 15, 1413 (2024).","journal-title":"Nat. Commun."},{"key":"20925_CR25","doi-asserted-by":"publisher","unstructured":"Razook, Z. et al. Real time, field-deployable whole genome sequencing of malaria parasites using nanopore technology. bioRxiv 2020.12.17.423341 (2020). https:\/\/doi.org\/10.1101\/2020.12.17.423341","DOI":"10.1101\/2020.12.17.423341"},{"key":"20925_CR26","doi-asserted-by":"publisher","first-page":"e0002743","DOI":"10.1371\/journal.pgph.0002743","volume":"4","author":"A Holzschuh","year":"2024","unstructured":"Holzschuh, A. et al. Using a mobile nanopore sequencing lab for end-to-end genomic surveillance of plasmodium falciparum: A feasibility study. PLOS Global Public. Health. 4, e0002743 (2024).","journal-title":"PLOS Global Public. Health"},{"key":"20925_CR27","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1038\/s41598-022-26935-z","volume":"13","author":"S Sabin","year":"2023","unstructured":"Sabin, S. et al. Portable and cost-effective genetic detection and characterization of plasmodium falciparum hrp2 using the minion sequencer. Sci. Rep. 13, 2893 (2023).","journal-title":"Sci. Rep."},{"key":"20925_CR28","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/jac\/dkae060","volume":"79","author":"S Hosch","year":"2024","unstructured":"Hosch, S. et al. PHARE: a bioinformatics pipeline for compositional profiling of multiclonal plasmodium falciparum infections from long-read nanopore sequencing data. J. Antimicrob. Chemother. 79, 987\u2013996 (2024).","journal-title":"J. Antimicrob. Chemother."},{"key":"20925_CR29","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.pt.2023.09.014","volume":"39","author":"WL Hamilton","year":"2023","unstructured":"Hamilton, W. L., Ishengoma, D. S., Parr, J. B., Bridges, D. J. & Barry, A. E. Nanopore sequencing for malaria molecular surveillance: opportunities and challenges. Trends Parasitol. 39, 996\u20131000 (2023).","journal-title":"Trends Parasitol."},{"key":"20925_CR30","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.pt.2024.10.001","volume":"40","author":"J Zerebinski","year":"2024","unstructured":"Zerebinski, J. & Plaza, D. F. Progress in malaria genomic surveillance using long-read sequencing. Trends Parasitol. 40, 956\u2013958 (2024).","journal-title":"Trends Parasitol."},{"key":"20925_CR31","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/cid\/ciab716","volume":"74","author":"EK Schmitt","year":"2022","unstructured":"Schmitt, E. K. et al. Efficacy of Cipargamin (KAE609) in a Randomized, phase II Dose-Escalation study in adults in Sub-Saharan Africa with uncomplicated plasmodium falciparum malaria. Clin. Infect. Dis. 74, 1831\u20131839 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"20925_CR32","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/infdis\/jiab352","volume":"225","author":"J Straimer","year":"2022","unstructured":"Straimer, J., Gandhi, P., Renner, K. C. & Schmitt, E. K. High prevalence of plasmodium falciparum K13 mutations in Rwanda is associated with slow parasite clearance after treatment with Artemether-Lumefantrine. J. Infect. Dis. 225, 1411\u20131414 (2022).","journal-title":"J. Infect. Dis."},{"key":"20925_CR33","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/s12936-021-04009-1","volume":"20","author":"G Ndayisaba","year":"2021","unstructured":"Ndayisaba, G. et al. Hepatic safety and tolerability of Cipargamin (KAE609), in adult patients with plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa. Malar. J. 20, 478 (2021).","journal-title":"Malar. J."},{"key":"20925_CR34","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s12936-017-2137-9","volume":"16","author":"RH Miller","year":"2017","unstructured":"Miller, R. H. et al. A deep sequencing approach to estimate plasmodium falciparum complexity of infection (COI) and explore apical membrane antigen 1 diversity. Malar. J. 16, 490 (2017).","journal-title":"Malar. J."},{"key":"20925_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-39656-7","volume":"9","author":"A Lerch","year":"2019","unstructured":"Lerch, A. et al. Longitudinal tracking and quantification of individual plasmodium falciparum clones in complex infections. Sci. Rep. 9, 1\u20138 (2019).","journal-title":"Sci. Rep."},{"key":"20925_CR36","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","volume":"373","author":"DE Neafsey","year":"2015","unstructured":"Neafsey, D. E. et al. Genetic diversity and protective efficacy of the RTS,S\/AS01 malaria vaccine. N. Engl. J. Med. 373, 2025\u20132037 (2015).","journal-title":"N. Engl. J. Med."},{"key":"20925_CR37","doi-asserted-by":"crossref","unstructured":"Holzschuh, A. Rapid multiplexed nanopore amplicon sequencing of Plasmodium falciparum microhaplotype loci protocol metrics. (2025).","DOI":"10.17504\/protocols.io.81wgbrqnqlpk\/v1"},{"key":"20925_CR38","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","volume":"13","author":"BJ Callahan","year":"2016","unstructured":"Callahan, B. J. et al. DADA2: High-resolution sample inference from illumina amplicon data. Nat. Methods. 13, 581\u2013583 (2016).","journal-title":"Nat. Methods"},{"key":"20925_CR39","doi-asserted-by":"crossref","unstructured":"Messerli, C., Hofmann, N. E., Beck, H. P. & Felger, I. Critical evaluation of molecular monitoring in malaria drug efficacy trials and pitfalls of Length-Polymorphic markers. Antimicrob. Agents Chemother 61, (2017).","DOI":"10.1128\/AAC.01500-16"},{"key":"20925_CR40","doi-asserted-by":"publisher","first-page":"e1005348","DOI":"10.1371\/journal.pcbi.1005348","volume":"13","author":"HH Chang","year":"2017","unstructured":"Chang, H. H. et al. THE REAL mccoil: A method for the concurrent Estimation of the complexity of infection and SNP allele frequency for malaria parasites. PLoS Comput. Biol. 13, e1005348 (2017).","journal-title":"PLoS Comput. Biol."},{"key":"20925_CR41","doi-asserted-by":"publisher","first-page":"1509261","DOI":"10.3389\/fpara.2024.1509261","volume":"3","author":"JM Sadler","year":"2025","unstructured":"Sadler, J. M. et al. Application of a new highly multiplexed amplicon sequencing tool to evaluate plasmodium falciparum antimalarial resistance and relatedness in individual and pooled samples from Dschang, Cameroon. Front. Parasitol. 3, 1509261 (2025).","journal-title":"Front. Parasitol."},{"key":"20925_CR42","doi-asserted-by":"publisher","first-page":"e0257521","DOI":"10.1371\/journal.pone.0257521","volume":"16","author":"C Delahaye","year":"2021","unstructured":"Delahaye, C. & Nicolas, J. Sequencing DNA with nanopores: troubles and biases. PLOS ONE. 16, e0257521 (2021).","journal-title":"PLOS ONE"},{"key":"20925_CR43","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature01097","volume":"419","author":"MJ Gardner","year":"2002","unstructured":"Gardner, M. J. et al. Genome sequence of the human malaria parasite plasmodium falciparum. Nature 419, 498\u2013511 (2002).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20925-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20925-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20925-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:15:12Z","timestamp":1761128112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20925-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["20925"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-20925-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.H. and C.N. have provided genotyping services to Novartis. A.L. declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36941"}}